Develops cell therapies for solid tumor cancers.
Jun 2026Revenue $325M/yrExpenses $626M/yr
No trendCash runway ≈ 1.0 years from Jun 2026
Figures by year
When will Iovance Biotherapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $325M and expenses $626M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $264M | $667M | −$403M |
| Dec 2024 | $164M | $559M | −$395M |
| Dec 2023 | $1.19M | $462M | −$461M |
| Dec 2018 | $0.00 | $128M | −$128M |
| Dec 2017 | $0.00 | $92.9M | −$92.9M |
| Dec 2016 | $0.00 | $53.6M | −$53.6M |
| Dec 2015 | $0.00 | $27.9M | −$27.9M |
| Dec 2014 | $0.00 | $12.0M | −$12.0M |
| Dec 2013 | $0.00 | $22.6M | −$22.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.